DAVID L. GRANGE - 13 May 2025 Form 4 Insider Report for Tonix Pharmaceuticals Holding Corp. (TNXP)

Role: Director
Signature: /s/ Jessica Morris, Attorney-in-Fact
Issuer symbol: TNXP
Transactions as of: 13 May 2025
Net transactions value: $0
Form type: 4
Filing time: 15 May 2025, 16:47:52 UTC
Previous filing: 24 May 2024
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
GRANGE DAVID L	Director	C/O TONIX PHARMACEUTICALS HOLDING CORP., 26 MAIN STREET, SUITE 101, CHATHAM	/s/ Jessica Morris, Attorney-in-Fact	15 May 2025	0001264908

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TNXP	Stock Option	Award	$0	+10,000		$0.000000	10,000	13 May 2025	Common Stock	10,000	$20.18	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan, as amended, and vests on the earlier of the one year anniversary of the grant date or the Issuer's 2026 Annual Meeting of Stockholders.